Vanessa Kennedy, MD, and other experts detailed novel targets, next-gen transplantation techniques and more.
Researchers believe that engineering chimeric antigen receptor (CAR) T cells to recognize CD155 is a novel approach that could be appropriate for both hematologic and solid tumors.